The intramuscular pharmacokinetics of ticarcillin and amikacin in rats receiving I ml of 5% mucin suspension (equivalent to 250 mg/kg) administered intraperitoneally were not altered compared with the control animals. However, it is important to investigate the effect of mucin on the pharmacokinetics of antimicrobial agents in animals which are used to evaluate the efficacy of the agents.
Rodents that are made neutropenic have been used to investigate the efficacy of antibiotic therapy in intra-abdominal sepsis. Sepsis is usually established by injecting microorganisms directly into the peritoneal cavity.
Porcine gastric mucin, administered intraperitoneally at the time of intraperitoneal bacterial challenge, reduces the number of bacteria necessary to establish fatal bacteraemias in rodent infection models (Nugester, Wolf & Jourdonais, 1932) . Although mucin is widely utilized in animal models, little is known about its effect on antimicrobial pharmacokinetics.
Recently, Tsai and Leitner (1981) observed differences in antibiotic pharmacokinetics in mice receiving 0·5 ml of a 4% mucin suspension administered intraperitoneally. The time to reach peak concentration was delayed by 0·25-1 h and the apparent half-lives were increased by a factor of 3-6 for orally adminis-tered ampicillin, cephalexin, cefadroxil and dicloxacillin. The apparent half-lives were increased by a factor of 1·4-2 for intramuscularly administered ampicillin, ceforanide and amikacin.
Similar models of infection in rats commonly use 1 ml of a 5% mucin suspension (Lumish & Norden, 1976; Winston et al., 1979) . Whilst this dose is less than that used by Tsai and Leitner (1981) on a per body weight basis (approximately 700 mg/kg and 250 mg/kg for mice and rats respectively), no information is currently available concerning the effect of mucin on antibiotic pharmacokinetics in the rat.
Accordingly, we studied the pharmacokinetic parameters (absorption rate, elimination rate, clearance, peak concentration and time to peak) of ticarcillin (lao mg/kg) (Beecham Labs, Bristol, TN) and amikacin (11 mg/kg) (Bristol Labs, Syracuse, NY) in female Sprague Dawley rats (180-200 g; Taconic Farms, Germantown, NY). The rats were acclimatized for at least 1 week after arrival. They were housed in stainless steel cages and had access to water and rodent chow (Ralston Purina) ad libitum. Food was withdrawn 15-18 h prior to dosing. The drugs were administered intramuscularly with and without intraperitoneal injection of 1 ml 5% mucin (Sigma Chemical, St Louis, MO). The blood samples were obtained by making an incision at the end of the rat tail and 60 I-tlof blood were collected with Natelson heparinized capillary tubes.
Samples were collected every 5-10 min in the first hour and every 15-30 min for the next 3 h.
Ticarcillin concentrations in rat plasma were rats receiving It mglkg intramuscularly: e, with 1 ml 5% mucin intraperitoneally; 0, without mucin. These simulation curves are based on the mean pharmacokinetic parameters for each group Fig. 2 . Ticarcillin pharmacokinetic simulation curves for rats receiving 100 mglkg intramuscularly: "", with I m15% mucin intraperitoneally; 6., without mucin. These simulation curves are based on the mean pharmacokinetic parameters for each group.
determined by microbiological assay using Bacillus subtilis ATCC 6633 as a test organism. Amikacin concentrations in rat plasma were determined using fluorescent immunoassay (Ames TDA, Miles Lab, Elkhart, IN). The pharmacokinetic analyses were conducted with the aid of NONLIN (Metzler, Elfring & McEwen, 1974) . On the basis of the Student t test at the P = 0·05 level for the observed parameters for each group, the pharmacokinetics of the drugs did not differ significantly from those for control rats receiving the same dose of antibiotics but without mucin (Table 1 , Figs 1 and 2) .
Although the possibility that species differences account for the conflicting results between our study and that of Tsai and Leitner (1981) cannot be eliminated, it is likely that adverse effects on absorption, elimination and renal and liver clearance caused by mucin may only be evident if high doses are employed. Because of these possibilities it would be prudent for investigators using mucin in animal infection models to test the effects of mucin on antimicrobial pharmacokinetics prior to proceeding with therapeutic evaluation.
